BioVersys Set to Announce 2025 Financial Results and Business Update

Basel-based BioVersys AG, listed on SIX (BIOV), is preparing to release its full-year financial results for 2025. The clinical stage biopharmaceutical company, known for developing antibacterial products targeting multidrug-resistant bacteria, will publish these results on March 18, 2026.

The release will be followed by a conference call and webcast at 2:00 PM CET that same day. During this session, the management will provide insights into the financial outcomes, discuss business updates, and outline future strategic directions. This call will offer investors, analysts, and media representatives the opportunity to engage with the company and ask questions.

BioVersys focuses on innovations in the antimicrobial and microbiome fields, addressing pressing medical needs related to resistant bacterial infections. Its advanced R&D programs target hospital-acquired infections and tuberculosis, in collaboration with partners like GlaxoSmithKline.